nach oben

Erschienen in:

01.09.2011 | Epidemiology

Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes

verfasst von: Sarah J. Nyante, Marilie D. Gammon, Jay S. Kaufman, Jeannette T. Bensen, Dan Yu Lin, Jill S. Barnholtz-Sloan, Yijuan Hu, Qianchuan He, Jingchun Luo, Robert C. Millikan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Adipocytokines are produced by visceral fat, and levels may be associated with breast cancer risk. We investigated whether single nucleotide polymorphisms (SNPs) in adipocytokine genes adiponectin (ADIPOQ), leptin (LEP), and the leptin receptor (LEPR) were associated with basal-like or luminal A breast cancer subtypes. 104 candidate and tag SNPs were genotyped in 1776 of 2022 controls and 1972 (200 basal-like, 679 luminal A) of 2311 cases from the Carolina Breast Cancer Study (CBCS), a population-based case–control study of whites and African Americans. Breast cancer molecular subtypes were determined by immunohistochemistry. Genotype odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. Haplotype ORs and 95% CIs were estimated using Hapstat. Interactions with waist-hip ratio were evaluated using a multiplicative interaction term. Ancestry was estimated from 144 ancestry informative markers (AIMs), and included in models to control for population stratification. Candidate SNPs LEPR K109R (rs1137100) and LEPR Q223R (rs1137101) were positively associated with luminal A breast cancer, whereas ADIPOQ +45 T/G (rs2241766), ADIPOQ +276 G/T (rs1501299), and LEPR K656N (rs8129183) were not associated with either subtype. Few patterns were observed among tag SNPs, with the exception of 3 LEPR SNPs (rs17412175, rs9436746, and rs9436748) that were in moderate LD and inversely associated with basal-like breast cancer. However, no SNP associations were statistically significant after adjustment for multiple comparisons. Haplotypes in LEP and LEPR were associated with both basal-like and luminal A subtypes. There was no evidence of interaction with waist-hip ratio. Data suggest associations between LEPR candidate SNPs and luminal A breast cancer in the CBCS and LEPR intron 2 tag SNPs and basal-like breast cancer. Replication in additional studies where breast cancer subtypes have been defined is necessary to confirm these potential associations.

Nur mit Berechtigung zugänglich

Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49(1):22–34PubMedCrossRef

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271PubMedCrossRef

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217–1226PubMedCrossRef

Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5):1533–1539PubMedCrossRef

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG et al (2006) Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 295(21):2492–2502PubMedCrossRef

Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(Suppl 2):S72–S77PubMedCrossRef

Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline brca1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482–1485PubMed

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW et al (2005) Prediction of brca1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180PubMedCrossRef

Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the brca1 phenotype. Oncogene 25(43):5846–5853PubMedCrossRef

10.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef

11.

Schaffler A, Scholmerich J, Buechler C (2007) Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3(4):345–354PubMedCrossRef

12.

Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5(3):153–165PubMedCrossRef

13.

Fredriksson J, Carlsson E, Orho-Melander M, Groop L, Ridderstrale M (2006) A polymorphism in the adiponectin gene influences adiponectin expression levels in visceral fat in obese subjects. Int J Obes (Lond) 30(2):226–232CrossRef

14.

Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8(5):395–408PubMedCrossRef

15.

Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94(9):1221–1225PubMedCrossRef

16.

Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89(3):1102–1107PubMedCrossRef

17.

Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, Yuan SS (2006) Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237(1):109–114PubMedCrossRef

18.

Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS (2007) Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92(3):1041–1048PubMedCrossRef

19.

Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9(15):5699–5704PubMed

20.

Kang JH, Yu BY, Youn DS (2007) Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 22(1):117–121PubMedCrossRef

21.

Han CZ, Du LL, Jing JX, Zhao XW, Tian FG, Shi J, Tian BG, Liu XY, Zhang LJ (2008) Associations among lipids, leptin, and leptin receptor gene gin223arg polymorphisms and breast cancer in china. Biol Trace Elem Res 126(1–3):38–48PubMedCrossRef

22.

Mantzoros CS, Bolhke K, Moschos S, Cramer DW (1999) Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer 80(4):523–526PubMedCrossRef

23.

Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D (2000) Leptin and insulin growth factor i in relation to breast cancer (greece). Cancer Causes Control 11(5):383–388PubMedCrossRef

24.

Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, Olsson T (2004) Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat 86(3):191–196PubMedCrossRef

25.

Cleveland RJ, Gammon MD, Long CM, Gaudet MM, Eng SM, Teitelbaum SL, Neugut AI, Santella RM (2010) Common genetic variations in the lep and lepr genes, obesity and breast cancer incidence and survival. Breast Cancer Res Treat 120(3):745–752. doi:10.1007/s10549-009-0503-1 PubMedCrossRef

26.

Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C (2008) Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 68(9):3178–3184PubMedCrossRef

27.

Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L (2006) Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 6:38PubMedCrossRef

28.

Woo HY, Park H, Ki CS, Park YL, Bae WG (2006) Relationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea. Cancer Lett 237(1):137–142PubMedCrossRef

29.

Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, Feigelson HS (2009) No association between polymorphisms in lep, lepr, adipoq, adipor1, or adipor2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 18(9):2553–2557. doi:10.1158/1055-9965.EPI-09-0542 PubMedCrossRef

30.

Okobia MN, Bunker CH, Garte SJ, Zmuda JM, Ezeome ER, Anyanwu SN, Uche EE, Kuller LH, Ferrell RE, Taioli E (2008) Leptin receptor gln223arg polymorphism and breast cancer risk in Nigerian women: a case control study. BMC Cancer 8:338PubMedCrossRef

31.

Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef

32.

Kristensen VN, Borresen-Dale AL (2008) Snps associated with molecular subtypes of breast cancer: on the usefulness of stratified genome-wide association studies (gwas) in the identification of novel susceptibility loci. Mol Oncol 2(1):12–15PubMedCrossRef

33.

Nordgard SH, Johansen FE, Alnaes GI, Naume B, Borresen-Dale AL, Kristensen VN (2007) Genes harbouring susceptibility snps are differentially expressed in the breast cancer subtypes. Breast Cancer Res 9(6):113PubMedCrossRef

34.

Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM (2009) In vitro and in vivo analysis of b-myb in basal-like breast cancer. Oncogene 28(5):742–751PubMedCrossRef

35.

Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET (1995) The Carolina breast cancer study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35(1):51–60PubMedCrossRef

36.

Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L (2003) Her2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79(3):355–364PubMedCrossRef

37.

Weinberg CR, Sandler DP (1991) Randomized recruitment in case-control studies. Am J Epidemiol 134(4):421–432PubMed

38.

Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151(7):703–714PubMed

39.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374PubMedCrossRef

40.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38(2):197–204PubMedCrossRef

41.

de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37(11):1217–1223PubMedCrossRef

42.

Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74(1):106–120PubMedCrossRef

43.

Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H et al (2007) A second generation human haplotype map of over 3.1 million snps. Nature 449(7164):851–861PubMedCrossRef

44.

Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC (2010) Fgfr2 and other loci identified in genome-wide association studies are associated with breast cancer in african-american and younger women. Carcinogenesis 31(8):1417–1423. doi:10.1093/carcin/bgq128 PubMedCrossRef

45.

Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF (2006) A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 79(4):640–649PubMedCrossRef

46.

Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR (2008) Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol Biomarkers Prev 17(3):471–477PubMedCrossRef

47.

Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 76(5):887–893PubMedCrossRef

48.

Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG (2005) Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev 14(6):1545–1551PubMedCrossRef

49.

Hall IJ, Newman B, Millikan RC, Moorman PG (2000) Body size and breast cancer risk in black women and white women: the carolina breast cancer study. Am J Epidemiol 151(8):754–764PubMed

50.

Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef

51.

Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF (2002) A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer 44(2):127–138PubMedCrossRef

52.

Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of ld and haplotype maps. Bioinformatics 21(2):263–265PubMedCrossRef

53.

Poole C (2001) Low P-values or narrow confidence intervals: which are more durable? Epidemiology 12(3):291–294PubMedCrossRef

54.

Lettre G, Lange C, Hirschhorn JN (2007) Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol 31(4):358–362PubMedCrossRef

55.

Lin DY (2005) An efficient Monte Carlo approach to assessing statistical significance in genomic studies. Bioinformatics 21(6):781–787. doi:10.1093/bioinformatics/bti053 PubMedCrossRef

56.

Lin DY, Zeng D, Millikan R (2005) Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 29(4):299–312PubMedCrossRef

57.

Lin DY, Zeng D (2006) Likelihood-based inference on haplotype effects in genetic association studies. J Am Stat Assoc 101(473):89–118CrossRef

58.

Hu YJ, Lin DY, Zeng D (2010) A general framework for studying genetic effects and gene–environment interactions with missing data. Biostatistics 11(4):583–598. doi:10.1093/biostatistics/kxq015 PubMedCrossRef

59.

Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI (2001) A single nucleotide polymorphism (snp) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108(3):233–236PubMedCrossRef

60.

van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC (2003) Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. Obes Res 11(3):377–386PubMedCrossRef

61.

Wauters M, Mertens I, Chagnon M, Rankinen T, Considine RV, Chagnon YC, Van Gaal LF, Bouchard C (2001) Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord 25(5):714–720PubMedCrossRef

62.

Kim SM, Kim SH, Lee JR, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY (2008) Association of leptin receptor polymorphisms lys109arg and gln223arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol 198(4):e421–e428. doi:10.1016/j.ajog.2007.10.799 CrossRef

63.

Ogawa T, Hirose H, Yamamoto Y, Nishikai K, Miyashita K, Nakamura H, Saito I, Saruta T (2004) Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism 53(7):879–885PubMedCrossRef

64.

Stratigopoulos G, Le Duc CA, Matsuoka N, Gutman R, Rausch R, Robertson SA, Myers MG Jr, Chung WK, Chua SC Jr, Leibel RL (2009) Functional consequences of the human leptin receptor (lepr) q223r transversion. Obesity (Silver Spring) 17(1):126–135. doi:10.1038/oby.2008.489 CrossRef

65.

Ragin CC, Dallal C, Okobia M, Modugno F, Chen J, Garte S, Taioli E (2009) Leptin levels and leptin receptor polymorphism frequency in healthy populations. Infect Agent Cancer 4(Suppl 1):13. doi:10.1186/1750-9378-4-S1-S13 CrossRef

66.

Ben Ali S, Kallel A, Sediri Y, Ftouhi B, Feki M, Slimene H, Jemaa R, Kaabachi N (2009) Lepr p.Q223r polymorphism influences plasma leptin levels and body mass index in Tunisian obese patients. Arch Med Res 40(3):186–190. doi:10.1016/j.arcmed.2009.02.008 PubMedCrossRef

67.

Savitz DA (2003) Interpreting epidemiologic evidence. Oxford University Press, New YorkCrossRef

Titel: Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes
verfasst von: Sarah J. Nyante
Marilie D. Gammon
Jay S. Kaufman
Jeannette T. Bensen
Dan Yu Lin
Jill S. Barnholtz-Sloan
Yijuan Hu
Qianchuan He
Jingchun Luo
Robert C. Millikan
Publikationsdatum: 01.09.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1517-z

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes

Abstract

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Surgery of the primary tumor does not improve survival in stage IV breast cancer

Dietary fiber is associated with circulating concentrations of C-reactive protein in breast cancer survivors: the HEAL study

Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study

Association of XPC polymorphisms with breast cancer risk

Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma

Biologic markers determine both the risk and the timing of recurrence in breast cancer

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie